The identification of colorectal cancer (CRC) patients that will benefit from adjuvant chemotherapy after surgical resection poses a major unmet need in providing their safest and most effective care. The current practice results in under-treatment of high-risk stage II patients and overtreatment of low-risk stage III patients. The core obstacle is the lack of a definitive diagnostic biomarker(s) to identify cancers with a high probability of metastasis and corresponding poor clinical outcome. Translation of microarray-based profiles into clinical diagnostics is complicated by their complexity, as well as by logistical, cost and regulatory barriers. Pathological assessment of solid tumors typically Involves immunohistochemistry and other immunoassays to detect protein expression in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Thus, there Is a gap between an emerging body of genomic information and diagnostic application. We propose to fill this gap by combining emerging genomic and proteomic technologies to identify and validate new molecular markers of colorectal cancer recurrence using FFPE tissue samples. We hypothesize that molecular encoding of a recurrence-prone phenotype in CRC is reflected by both transcriptomic and proteomic features. We will combine high-dimensional network analysis and new, targeted analysis platforms for specific transcripts and proteins to develop and test new biomarkers in archival FFPE specimens. We will test this hypothesis and develop these approaches according to the following specific aims:
Aim 1 : Develop our 34-gene nucleic acid-based colon cancer prognostic classifier for use in FFPE tissue samples and refine through a competitive evaluation of selected and published signature elements, using the novel nCounter multiplex expression analysis approach. We will use high-dimensional network models to predict protein biomarker candidates, which will be systematically evaluated with targeted proteomic analyses.
Aim 2 : Identify candidate protein biomarkers by targeted proteomics analysis.
Aim 3 : Test the protein-based and nucleic acid-based signature biomarkers in an independent set of archived colon cancer tissue samples annotated with patient outcomes.
There is a great need for an accurate and reliable method to identify colorectal patients at greatest risk for metastatic recurrence of disease who would potentially benefit from systemic therapy, and conversely to identify patients at low risk and who do not benefit from chemotherapy. This project addresses this important unmet need: the identification of molecular biomarkers that can segregate patients at high risk for metastatic recurrence from those at low risk with implications for differential personalized therapy.
|Schulte, Michael L; Fu, Allie; Zhao, Ping et al. (2018) Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat Med 24:194-202|
|Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191|
|Wang, Yang; Vnencak-Jones, Cindy L; Cates, Justin M et al. (2018) Deciphering Elevated Microsatellite Alterations at Selected Tetra/Pentanucleotide Repeats, Microsatellite Instability, and Loss of Heterozygosity in Colorectal Cancers. J Mol Diagn 20:366-372|
|Banerjee, Amrita; McKinley, Eliot T; von Moltke, Jakob et al. (2018) Interpreting heterogeneity in intestinal tuft cell structure and function. J Clin Invest 128:1711-1719|
|Herring, Charles A; Chen, Bob; McKinley, Eliot T et al. (2018) Single-Cell Computational Strategies for Lineage Reconstruction in Tissue Systems. Cell Mol Gastroenterol Hepatol 5:539-548|
|Choi, Eunyoung; Lantz, Tyler L; Vlacich, Gregory et al. (2018) Lrig1+ gastric isthmal progenitor cells restore normal gastric lineage cells during damage recovery in adult mouse stomach. Gut 67:1595-1605|
|Singh, Kshipra; Coburn, Lori A; Asim, Mohammad et al. (2018) Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. Cancer Res 78:4303-4315|
|Idrees, Kamran; Padmanabhan, Chandrasekhar; Liu, Eric et al. (2018) Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. J Surg Oncol 117:284-289|
|Zhang, Qin; Jeppesen, Dennis K; Higginbotham, James N et al. (2018) Mutant KRAS Exosomes Alter the Metabolic State of Recipient Colonic Epithelial Cells. Cell Mol Gastroenterol Hepatol 5:627-629.e6|
|Choksi, Yash A; Reddy, Vishruth K; Singh, Kshipra et al. (2018) BVES is required for maintenance of colonic epithelial integrity in experimental colitis by modifying intestinal permeability. Mucosal Immunol 11:1363-1374|
Showing the most recent 10 out of 447 publications